In a previous open study 3 patients with severe juvenile rheumatoid arthritis (JRA) were treated with 5 to 10 injections of transfer factor for 3 to 5 months Kass et al., 1974; Natvig et al., 1976) . No flare-up of the disease or clinical progression occurred, but there was general clinical improvement and in 2 cases joint function improved as well. There were some concomitant changes in cell-mediated immunity, with conversion of previously negative responses to antigens in delayed hypersensitivity in vivo and lymphocyte transformation in vitro.
These results may not have been due to the effect of transfer factor, however, but could have been caused by factors such as spontaneous recovery, other treatment, placebo effect, milieu factors, or bias or error in evaluation of the different parameters. We therefore decided to carry out a controlled clinical trial. Because of the relatively large fluctuations in disease activity with time, a parallel rather than a cross-over trial was conducted, with one group treated with transfer factor and one group treated with placebo (Hill, 1969; Amor et al., 1974) .
Accepted for publication August 10, 1977 Correspondence to Dr H. M. H0yeraal, Oslo Sanitetsforening Rheumatism Hospital, Oslo 1, Norway We present the results of the clinical and immunological evaluation of 12 patients treated with transfer factor and 12 patients treated with placebo. Immunological evaluation included in vitro stimulation of lymphocyte reactivity and delayed hypersensitivity skin testing as well as peripheral blood lymphocyte population studies.
Patients
The 24 patients were diagnosed according to the criteria of Ansell and Bywaters (1969) . Patients in complete remission and those with very severe disease possibly requiring surgical treatment or a change in medical treatment during the trial were excluded. A minimum of 4 weeks elapsed between an operation and the start of the trial. None of the patients had had skin tests with any antigen preparation during the preceding 3 months. The mean age of the patients was 11.6 years (range 7 to 16 years). 3 patients belonged to functional class I and 21 to class II according to Steinbrocker et al. (1949) . The type of onset, according to the criteria of Calabro and Marchesano (1968) (Husby et al., 1973) .
Treatment was unaltered during the trial. Before and during the trial 22 patients received salicylates, 1 naproxen, 4 chloroquine preparations, 1 a maintenance dose of gold salts, and 3 low-dose corticosteroids. The trial was carried out on outpatients as well as inpatients at the Oslo Sanitetsforening Rheumatism Hospital between June 1974 and August 1975. Informed consent was obtained from the patients and their parents.
Materials and methods TRANSFER FACTOR AND PLACEBO
Transfer factor was prepared from 250 to 600 x 106 lymphocytes obtained from 400 to 450 ml venous blood (heparin 0-01 IU/l) from normal adult blood donors. Details of cell extraction, freezing and thawing, dialysis, and lyophilisation were as described previously . The dialysates containing transfer factor were then dissolved in 4-5 ml distilled water and sterilised by passage through a 0.22 ,um millipore filter. Physiological saline was used as placebo. The injections were made subcutaneously in the deltoid area.
DESIGN OF TRIAL
The trial was double blind. The patients were randomised so that 12 received injections of transfer factor and 12 placebo. Only the statisticians and a nonmedical person who stored the preparations in a -20°C freezer knew the code until all the clinical and laboratory tests had been evaluated. The observation period was 6 months. The schedule of treatment and evaluation is given in Table 1 . Each patient received injections every fortnight for the first 3 months and thereafter at monthly intervals. Clinical evaluations and several laboratory tests were performed monthly. Estimation of lymphocyte populations in peripheral blood and evaluation Cell-mediated immunity in vitro This was studied by lymphocyte transformation after stimulation with a panel of unspecific and specific mitogens as previously described (H0yeraal et al., 1975) . The unspecific mitogens used were phytohaemagglutinin, pokeweed mitogen, and concanavalin A. The specific antigens used were preparations of Candida albicans and purified derivatives of tuberculin. Mitomycin C-treated allogeneic cells in mixed lymphocyte culture tests were also used.
Cell-mediated immunity in vivo
This was studied by delayed skin hypersensitivity as reported elsewhere (H0yeraal et al., 1975 
Results
One patient in the placebo group was excluded from the trial after 3 months because of severe exacerbation of the disease. There was no significant difference between the two groups in the change in pain and morning stiffness as assessed by the patients (Table 2) , nor with regard to the objective evaluation of doctors and physiotherapists, nor with (Table  3) , but the significance was marginal. A somewhat greater reduction in absolute number of T lymphocytes also occurred in the transfer factor group compared to the placebo group, but this difference was not significant. No significant difference was found between the two groups with regard to alteration in the absolute number of leucocyte or lymphocyte counts in peripheral blood or in the percentage or absolute number of B lymphocytes and Fc-receptor bearing lymphoid cells (Table 3) .
Furthermore, the changes in cell-mediated immunity, estimated by tests in vitro (Table 4 ) and in vivo (Table 5) , did not differ significantly between the two groups. Similar observations were made when diameters of erythema rather than induration were used. As a result of randomisation of the patients into two groups, only 2 patients in the transfer factor-treated group had been tested before this trial, whereas 7 in the placebo group had been, giving a one-sided value of P=004 by the FisherIrwin test for 2-by-2 tables. Technical difficulties with some in vitro cellular studies reduced the number of patients somewhat (Tables 3, 4) .
No side effects could be related to the treatment with transfer factor. The results indicate that transfer factor injections caused neither a flare-up nor a worsening of the disease, nor clinical improvement of the arthritis.
Discussion
The preparations of transfer factor used were not found to be of any significant therapeutic value for the JRA patients, as assessed by several criteria of disease activity and immunological function. On the other hand, this trial did not make the patients worse clinically. These findings are in accordance with a double-blind 12-week crossover trial in 6 adults with rheumatoid arthritis (Maini et al., 1976) , and with an open trial of 8 patients with JRA (Gr0hn et al., 1976) . In rheumatic diseases with a natural fluctuating course, a longer period (6 months) and a parallel group study are considered more convenient for documenting toxicity and for demonstrating possible specific activity (Hill, 1969; Amor et al., 1974; Fr0land et al., 1974; Gr0hn et al., 1976; Maini et al., 1976) . As there are still no uniformly accepted diagnostic criteria of JRA and no simple ways of estimating disease activity (Hill, 1969; McCarty, 1972; Amor et al., 1974; Levy and Dick, 1975) , a panel of subjective and objective criteria was used. Extensive planning before the trial, the help of statisticians, and regular discussions by the team of investigators during the trial were valuable.
In a study with so many variables, random allocation and wholly unbiased observations are an absolute necessity. The significance of the greater reduction of the percentage of T lymphocytes in the peripheral blood from transfer factor-treated patients than from that of placebo-treated patients is difficult to explain. When performing several statistical analyses on material, however, some reach statistical significance by chance.
No significant potentiation of cell-mediated immunity was found in the patients treated with transfer factor by comparison with the reactivity observed in the placebo group. This is in contrast to the observations made in the open pilot study Kass et al., 1974; Natvig et al., 1976) . The immunopotentiation in those 3 patients may have been due to sensitisation by repeated skin testing (Gr0hn et al., 1976; Maini et al., 1976) . In order to eliminate this possibility in this study, skin testing was only performed before or after completing the trial. This discrepancy between the results obtained in the pilot and the present study may be due to the great difference in frequency of previous testing in patients in the two groups. More than half of the patients in the placebo group had had skin tests, whereas only 1 out of 6 of the transfer factor-treated patients had.
In conclusion, the transfer factor preparations from healthy blood donors were of no therapeutic value for these JRA patients. We have now stopped using such preparations in the treatment of JRA. The nature of a possible antigen(s) involved in the pathogenesis of JRA is(are) still unknown. Thus, more specific or purified preparations of transfer factor seem to be required if further trials are conducted in patients with JRA.
